Latest Hospitality News

Lark Distilling Co. Ltd reported a 7% increase in net sales revenue for Q2FY25, driven by strong growth in direct-to-consumer, global travel retail, and export channels despite domestic B2B challenges. The company is advancing its brand restage and maintaining solid cash reserves.

Alcidion Group Limited reported robust Q2 FY25 sales of $13.1 million and improved cash flow, reinforcing its forecast to achieve EBITDA and cashflow positivity by the end of FY25.

Tissue Repair Limited has commenced patient randomisation in its Phase 3 trial of TR987®, targeting chronic venous leg ulcers, aiming to confirm promising earlier results and potentially transform wound healing treatment.

Artrya Limited reports solid progress on its FDA 510(k) application and secures a A$5 million capital raise, positioning itself for imminent commercial rollout in the US healthcare sector.

CurveBeam AI has reported a record quarter for HiRise™ device purchase orders, driven by a strategic expansion with Stryker in Australia and New Zealand. The company also advanced its FDA regulatory pathway for its BMD module, setting sights on mid-2025 submission.

The Star Entertainment Group has agreed to sell its Sydney Event Centre assets to Foundation Theatres for $60 million, marking a strategic shift in its property portfolio.

TrivarX has secured positive feedback from the FDA on its pivotal trial design for MEB-001, an AI-driven algorithm targeting major depressive episode screening via sleep study data. The company is advancing site collaborations to launch a large-scale US trial.

OncoSil Medical has achieved a key regulatory milestone with MDR certification from BSI, removing post-market restrictions and streamlining its commercial operations across Europe. This approval also paves the way for renewed efforts to enter the Australian market.

CurveBeam AI has broadened its commercial agreement with Stryker to cover Australia and New Zealand, aiming to accelerate adoption of its HiRise weight bearing CT scanners through targeted surgeon education and promotion.

EMVision Medical Devices reports strong progress in clinical trials for its emu™ Bedside Scanner, backed by robust cash reserves and strategic non-dilutive funding. The company is poised to commence pivotal FDA validation trials, marking a key step toward commercialisation.

Oneview Healthcare reported a robust Q4 2024 cash flow update, bolstered by a significant equity raise and expanding partnerships, positioning the company for accelerated growth in 2025.

Clarity Pharmaceuticals has secured a second FDA Fast Track Designation for its 64Cu-SAR-bisPSMA diagnostic agent, aiming to revolutionize prostate cancer imaging and speed regulatory approval.